Comments to the author: The experiments are logical and the results appear sound. My issues with the manuscript are mostly in regards to the amount of content provided and some of the stylistic choices made by the author. The figures could be better organized. There should also be greater transparency within the body of the manuscript regarding the use of HeLa cells in the in vitro experiments. Why were these cells used instead of cultured neurons or retinal ganglion cells? Finally, a bit more evidence (i.e. immunostaining) could be provided that proves that retinal ganglion cells and cells of the inner nuclear layer are indeed spared after drug treatment. However, the findings are interesting and I believe that publishing a perspective on these experiments would be valuable to the journal. Also, because it is a perspective, no new experiments are necessary. In this manuscript, the authors demonstrated that treatment with a battery of synthesized valosin-containing protein (VCP) modulators (KUS) in a rat model of retinal artery occlusion (CRAO) results in significant neuroprotection in the retina. It is hypothesized that VCP functions as an ATPase, which in the context of ischemic injury, exacerbates ATP depletion resulting in heightened endoplasmic reticular stress and subsequent cellular degeneration. However, it has been previously demonstrated that VCP functions in several capacities within the cell and its total knockdown is cytotoxic. Therefore, the authors screened for VCP modulators that inactivate or lessen VCP mediated ATP hydrolysis without producing secondary damage to the retina In the first series of experiments (figure 1), the authors provide several lines of evidence in HeLa cells that KUS compounds both decrease ATPase activity and lessen ER stress by reducing levels of C/EBP homologous protein, "an ER stress-induced molecule". Though the evidence is quite convincing, the authors should provide some continuity between the experiments. That is, provide data on luciferase activity with the addition of K69 and K94 compounds along with the K121 compound. It should be also noted in the body of the textnot just the figure legend -that these experiments were done in HeLA cells and provide justification of the use of this cell line instead of neuronal cultures. Also, it is unclear what "HG", "(-)", and "D" stands for in Figure 1A and B. In the second series of experiments (figure 2), KUS121 was intravitreally injected into a Thy1-GFP rat model of retinal ischemia. Several assays were conducted, which demonstrate structural and functional protection after administration of KUS121. In lieu of the graphics which demonstrate the experimental time line and the route of drug administration, provide images and quantifications of changes in cellular density after KUS121 administration. Discuss which methods you used to quantify apoptosis or cell loss. It was mentioned that there were changes in cellular density in the inner nuclear layer (INL). The INL is composed of a variety of cell types (amacrine, bipolar, horizontal, etc). Which cells were spared from apoptosis and how did you distinguish between these cell types? Finally, it is interesting that KUS121 significantly increases b-wave amplitude after retinal ischemic injury. However, there appears to be a non-trivial difference in beta-wave amplitude in KUS121
